MedPath

Cost-effectiveness of a stepped care strategy to improve symptoms of depression or anxiety in patients treated for head and neck cancer or lung cancer.

Completed
Conditions
psychische stoornissen: angststoornissen en -symptomen
anxiety and depression
lung and head and neck neoplasms
10038666
10002861
Registration Number
NL-OMON39087
Lead Sponsor
Vrije Universiteit Medisch Centrum
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
152
Inclusion Criteria

Treatment for UICC stage I-IV lung or head and neck carcinoma: ICD-10 C00-C14 (lip, oral cavity and pharynx), C32 (larynx), C33 (trachea), C34 (lung); psychological distress or possible or probable cases of depression or anxiety as assessed by the Hospital Anxiety Depression Scale (HADS-Anxiety subscale score > 7 and/or HADS-Depression subscale score > 7, or total score on HADS > 14). For more details, see page 11 of the researchprotocol.

Exclusion Criteria

Other (neurological) diseases causing cognitive dysfunction; no motivation to undergo psychosocial therapy; current treatment for a depressive or anxiety disorder; end of treatment for a psychiatric disorder less than two months ago, high suicide risk; psychotic and/or manic signs; too little knowledge of the Dutch language to fill out the questionnaires.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary outcome is the Hospital Anxiety and Depression Scale (HADS) and costs<br /><br>(health care utilization and work loss (TIC-P and PRODISQ modules)).<br /><br></p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Secondary outcome measures are quality of life questionnaires (EORTC QLQ-C30,<br /><br>EORTC QLQ-HN35, EORTC QLQ-LC13) and patient satisfaction with care (EORTC<br /><br>QLQ-PATSAT).</p><br>
© Copyright 2025. All Rights Reserved by MedPath